Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables - Other: 2020-2024

Historic Receivables - Other for Fulcrum Therapeutics (FULC) over the last 5 years, with Dec 2024 value amounting to $2.1 million.

  • Fulcrum Therapeutics' Receivables - Other was N/A to $979,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $979,000, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 290.32% up from last year.
  • As of FY2024, Fulcrum Therapeutics' Receivables - Other stood at $2.1 million, which was up 290.32% from $537,000 recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Receivables - Other ranged from a high of $2.1 million in FY2024 and a low of $229,000 during FY2022.
  • Moreover, its 3-year median value for Receivables - Other was $537,000 (2023), whereas its average is $954,000.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 79.86% in 2022, then surged by 290.32% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Receivables - Other stood at $531,000 in 2020, then spiked by 114.12% to $1.1 million in 2021, then tumbled by 79.86% to $229,000 in 2022, then soared by 134.50% to $537,000 in 2023, then spiked by 290.32% to $2.1 million in 2024.